Evidence map›Paper›PMID 33796292›Full record

ArticleMolecular and clinical oncology2021

Clinical study of modulated electro-hyperthermia for advanced metastatic breast cancer.

Takuya Nagata, Masahiko Kanamori, Shinichi Sekine, Mie Arai, Makoto Moriyama, Tsutomu Fujii

Abstract read
In one paragraph

Article in Molecular and clinical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Takuya NagataDepartment of Surgery, Toho University Ohashi Medical Center, Tokyo 153-8515, Japan.
Masahiko KanamoriDepartment of Human Science, University of Toyama, Toyama 930-0194, Japan.
Shinichi SekineDepartment of Surgery, Kamiichi General Hospital, Toyama 930-0391, Japan.
Mie AraiDepartment of Surgery, Toyama Nishi General Hospital, Toyama 939-2716, Japan.
Makoto MoriyamaDepartment of Surgery, Tomei Atsugi Hospital, Kanagawa 243-8571, Japan.
Tsutomu FujiiDepartment of Science and Surgery, University of Toyama, Toyama 930-0194, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Modulated electro-hyperthermia (mEHT) is a new treatment modality developed to overcome the problems associated with traditional hyperthermia; mEHT uses a precise impedance-matched system and modulated radiofrequency current flow to malignant tumors. It selects the malignant cells based on their biophysical differences, due to their high metabolic rate, individual (autonomic) behavior and membrane status. The aim of the present study was to report the outcomes of mEHT in the treatment of advanced breast cancer. mEHT was examined in 10 patients with advanced metastatic breast cancer and recurrent disease, who were considered incurable by standard therapy protocols. Of the 10 patients, partial response was achieved in 3, disease stability in 3, and progressive disease in 4; however, their quality of life was improved based on their subjective reports. No adverse effects were observed in any of the 10 patients. The present study demonstrated the feasibility of mEHT as a possible therapy for advanced breast cancer cases when standard therapies fail. Moreover, mEHT had no side effects and may be combined with various treatments for long-term therapy.

Indexed as

breast cancerchemotherapyhyperthermiairradiation

Identifiers

PMID33796292
PMCPMC8010507

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.